AIM: E-cadherin is unusually highly expressed in most ovarian cancers. This study was designed to investigate the roles of E-cadherin in the carcinogenesis and progression of ovarian cancers. METHODS: Human ovarian adenocarcinoma cell line SKOV-3 was examined. E-cadherin gene CDH1 in SKOV-3 cells was knocked down via RNA interference (RNAi), and the resultant variation of biological behavior was observed using CCK-8 and colony formation experiment. E-cadherin-mediated Ca(2+)-dependent cell-cell adhesion was used to study the mechanisms underlying the effects of E-cadherin on the proliferation and survival of SKOV-3 cells. The expression levels of E-cadherin, extracellular signal-related kinase (ERK), phosphorylated ERK (P-ERK) were measured using Western blot assays. RESULTS: Transfection with CDH1-siRNA for 24-96 h significantly suppressed the growth and proliferation of SKOV-3 cells. E-cadherin-mediated calcium-dependent cell-cell adhesion of SKOV-3 cells resulted in a rapid increase of P-ERK, but did not modify the expression of ERK protein. The phosphorylation of ERK in the cells was blocked by pretreatment with the MEK1 specific inhibitor PD98059 (50 μmol/L), but not by the PI3K inhibitor wortmannin (1 μmol/L) or PKA inhibitor H89 (10 μmol/L). CONCLUSION: E-cadherin may function as a tumor proliferation enhancer via activating the MEK/ERK pathway in development of ovarian epithelial cancers.
AIM: E-cadherin is unusually highly expressed in most ovarian cancers. This study was designed to investigate the roles of E-cadherin in the carcinogenesis and progression of ovarian cancers. METHODS:Humanovarian adenocarcinoma cell line SKOV-3 was examined. E-cadherin gene CDH1 in SKOV-3 cells was knocked down via RNA interference (RNAi), and the resultant variation of biological behavior was observed using CCK-8 and colony formation experiment. E-cadherin-mediated Ca(2+)-dependent cell-cell adhesion was used to study the mechanisms underlying the effects of E-cadherin on the proliferation and survival of SKOV-3 cells. The expression levels of E-cadherin, extracellular signal-related kinase (ERK), phosphorylated ERK (P-ERK) were measured using Western blot assays. RESULTS: Transfection with CDH1-siRNA for 24-96 h significantly suppressed the growth and proliferation of SKOV-3 cells. E-cadherin-mediated calcium-dependent cell-cell adhesion of SKOV-3 cells resulted in a rapid increase of P-ERK, but did not modify the expression of ERK protein. The phosphorylation of ERK in the cells was blocked by pretreatment with the MEK1 specific inhibitor PD98059 (50 μmol/L), but not by the PI3K inhibitor wortmannin (1 μmol/L) or PKA inhibitor H89 (10 μmol/L). CONCLUSION:E-cadherin may function as a tumor proliferation enhancer via activating the MEK/ERK pathway in development of ovarian epithelial cancers.
Authors: Pradeep Reddy; Lian Liu; Chong Ren; Peter Lindgren; Karin Boman; Yan Shen; Eva Lundin; Ulrika Ottander; Miia Rytinki; Kui Liu Journal: Mol Endocrinol Date: 2005-05-31
Authors: Hyung-Gyoo Kang; Jasmine M Jenabi; Jingsong Zhang; Nino Keshelava; Hiroyuki Shimada; William A May; Tony Ng; C Patrick Reynolds; Timothy J Triche; Poul H B Sorensen Journal: Cancer Res Date: 2007-04-01 Impact factor: 12.701
Authors: E Daraï; J Y Scoazec; F Walker-Combrouze; N Mlika-Cabanne; G Feldmann; P Madelenat; F Potet Journal: Hum Pathol Date: 1997-08 Impact factor: 3.466
Authors: Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: H J Hugo; N P A D Gunasinghe; B G Hollier; T Tanaka; T Blick; A Toh; P Hill; C Gilles; M Waltham; E W Thompson Journal: Breast Cancer Res Date: 2017-07-27 Impact factor: 6.466
Authors: Lu Han; Yang Li; Jason Tchao; Aaron D Kaplan; Bo Lin; You Li; Jocelyn Mich-Basso; Agnieszka Lis; Narmeen Hassan; Barry London; Glenna C L Bett; Kimimasa Tobita; Randall L Rasmusson; Lei Yang Journal: Cardiovasc Res Date: 2014-09-10 Impact factor: 10.787